Literature DB >> 2021955

Feeder cells enhance oncolytic and proliferative activity of long-term human bone marrow interleukin-2 cultures and induce different lymphocyte subsets.

P R Fuchshuber1, E Lotzová.   

Abstract

The effect of feeder cells on oncolytic activity of lymphocyte subsets and their growth was evaluated in long-term human bone marrow interleukin-2 (IL-2) cultures. Two B-lymphoblastoid cell lines (Daudi and Epstein-Barr-virus-transformed BSM) and two human leukemias, AML-M5, were used as feeder cells. The most prominent effects were seen in cultures stimulated with Daudi cells. In these cultures, cytotoxic activity was 100-1000 times increased against a broad range of target cells and the total cellular expansion was more than 40 times higher than in control cultures. This Daudi-related effect appeared to be mediated by natural killer (NK) cells, since cellular expansion occurred mostly in the CD16+ and CD56+ CD3- NK cell subset. In cultures stimulated with BSM and acute myelogenous leukemia (AML) feeder cells, the increase in proliferation was similar, but the enhancement of cytotoxicity, even though significant, was less prominent. Although all feeder cells were effective in stimulation of bone marrow reactivity, the highest cytotoxicity was always observed with feeder cells autologous to the targets, indicating some degree of specificity. This was especially evident in cultures stimulated with autologous versus allogeneic AML feeder cells. In contrast to Daudi-stimulated IL-2 cultures, in which the highest expansion of CD3- CD56+ NK cells was observed, in BSM and AML cultures, the CD3+ CD56+/-T cell subsets were more prolific. This indicates that the response and phenotypic heterogeneity of bone marrow cultures depends on the type of feeder cells used. This observation indicates that the preferential stimulation of a pertinent lymphocyte subset for therapeutic purposes may be possible.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2021955     DOI: 10.1007/bf01742522

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  15 in total

1.  Natural killer cells: definition, heterogeneity, lytic mechanism, functions and clinical application. Highlights of the Fifth International Workshop on natural killer cells, Hilton Head Island, N.C., March 1988.

Authors:  E Lotzová; E W Ades
Journal:  Nat Immun Cell Growth Regul       Date:  1989

2.  Cytotoxicity and clinical application of activated NK cells.

Authors:  E Lotzová
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

3.  Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines.

Authors:  B Perussia; C Ramoni; I Anegon; M C Cuturi; J Faust; G Trinchieri
Journal:  Nat Immun Cell Growth Regul       Date:  1987

Review 4.  Reassessment of LAK phenomenology: a review.

Authors:  E Lotzová; R B Herberman
Journal:  Nat Immun Cell Growth Regul       Date:  1987

Review 5.  Human natural killer cells: biologic and pathologic aspects.

Authors:  G Trinchieri; B Perussia
Journal:  Lab Invest       Date:  1984-05       Impact factor: 5.662

6.  Auto-tumor lysis by blood lymphocytes in vitro. Strongly activated lymphocytes lack selectivity.

Authors:  F Vánky; E Klein
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Induction of NK cell activity against fresh human leukemia in culture with interleukin 2.

Authors:  E Lotzová; C A Savary; R B Herberman
Journal:  J Immunol       Date:  1987-04-15       Impact factor: 5.422

8.  Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1.

Authors:  B Perussia; S Starr; S Abraham; V Fanning; G Trinchieri
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

9.  Lymphokine-activated killer cells. Analysis of progenitors and effectors.

Authors:  J R Ortaldo; A Mason; R Overton
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

10.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.

Authors:  M Kobayashi; L Fitz; M Ryan; R M Hewick; S C Clark; S Chan; R Loudon; F Sherman; B Perussia; G Trinchieri
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

View more
  4 in total

1.  Induction of cytotoxic lymphocyte subsets against leukemia by stimulation with AML blasts.

Authors:  E Lotzová; C A Savary
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

2.  Development of NK cell expansion methods using feeder cells from human myelogenous leukemia cell line.

Authors:  Duk Seong Bae; Jae Kwon Lee
Journal:  Blood Res       Date:  2014-09-25

Review 3.  Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation.

Authors:  Markus Granzin; Juliane Wagner; Ulrike Köhl; Adelheid Cerwenka; Volker Huppert; Evelyn Ullrich
Journal:  Front Immunol       Date:  2017-04-26       Impact factor: 7.561

Review 4.  Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.

Authors:  Erica L Heipertz; Evan R Zynda; Tor Espen Stav-Noraas; Andrew D Hungler; Shayne E Boucher; Navjot Kaur; Mohan C Vemuri
Journal:  Front Immunol       Date:  2021-12-01       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.